| Literature DB >> 24273721 |
Axel Lipp1, Radmila Trbojevic, Friedemann Paul, Andreas Fehlner, Sebastian Hirsch, Michael Scheel, Cornelia Noack, Jürgen Braun, Ingolf Sack.
Abstract
Detection and discrimination of neurodegenerative Parkinson syndromes are challenging clinical tasks and the use of standard T1- and T2-weighted cerebral magnetic resonance (MR) imaging is limited to exclude symptomatic Parkinsonism. We used a quantitative structural MR-based technique, MR-elastography (MRE), to assess viscoelastic properties of the brain, providing insights into altered tissue architecture in neurodegenerative diseases on a macroscopic level. We measured single-slice multifrequency MRE (MMRE) and three-dimensional MRE (3DMRE) in two neurodegenerative disorders with overlapping clinical presentation but different neuropathology - progressive supranuclear palsy (PSP: N = 16) and idiopathic Parkinson's disease (PD: N = 18) as well as in controls (N = 18). In PSP, both MMRE (Δμ = - 28.8%, Δα = - 4.9%) and 3DMRE (Δ|G*|: - 10.6%, Δφ: - 34.6%) were significantly reduced compared to controls, with a pronounced reduction within the lentiform nucleus (Δμ = - 34.6%, Δα = - 8.1%; Δ|G*|: - 7.8%, Δφ: - 44.8%). MRE in PD showed a comparable pattern, but overall reduction in brain elasticity was less severe reaching significance only in the lentiform nucleus (Δμ n.s., Δα = - 7.4%; Δ|G*|: - 6.9%, Δφ: n.s.). Beyond that, patients showed a close negative correlation between MRE constants and clinical severity. Our data indicate that brain viscoelasticity in PSP and PD is differently affected by the underlying neurodegeneration; whereas in PSP all MRE constants are reduced and changes in brain softness (reduced μ and |G*|) predominate those of viscosity (α and φ) in PD.Entities:
Keywords: Elasticity; MR-elastography; MRE; Parkinson disease; Progressive supranuclear palsy; Viscosity
Year: 2013 PMID: 24273721 PMCID: PMC3814959 DOI: 10.1016/j.nicl.2013.09.006
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Patient characteristics.
| Parameter | Controls | PD | PSP | |
|---|---|---|---|---|
| N | 18 | 18 | 16 | |
| Gender [f: m] | 8: 11 | 6: 12 | 8: 8 | |
| Age [years] | 64 ± 10.8 | 63 ± 10.8 | 70 ± 5.8 | 0.07 |
| Disease duration [months] | n.a. | 111 ± 81.0 | 69 ± 32.4 | 0.14 |
| Clinical severity | n.a. | 16.7 ± 9.8 | 41.9 ± 12.5 |
Values are means ± SD.
Kruskal–Wallis test.
Mann–Whitney test.
Clinical severity in PD and PSP cases assessed by motor part of UPDRS and Golbe scale.
Fig. 1Group-wise comparison of MMRE parameters μ and α within the lentiform nuclei; values are group means [SD], *P < 0.05, unpaired t-test.
Fig. 3Group-wise comparison of 3DMRE parameters |G*| and φ within the lentiform nuclei; values are group means [SD], *P < 0.05, unpaired t-test.
Fig. 2Normalised parameter maps obtained by 3DMRE. The grayscale in the |G*| maps is from 0 to 3 kPa, the colorscale of phi is from 0 to 0.2. (For interpretation of the references to colour in this figure, the reader is referred to the web version of this article.)
Brain viscoelastic parameters.
| Viscoelasticity parameters | Controls | PD | PSP | |
|---|---|---|---|---|
| MMRE — full brain | ||||
| μ [Pa] | 2788 ± 302 | 3038 ± 814 | 1984 ± 489 | < 0.001 |
| α | 0.303 ± 0.014 | 0.295 ± 0.018 | 0.288 ± 0.012 | 0.02 |
| MMRE — lentiform nucleus | ||||
| μ [Pa] | 3961 ± 997 | 3907 ± 1211 | 2475 ± 1036 | < 0.001 |
| α | 0.349 ± 0.03 | 0.322 ± 0.03 | 0.319 ± 0.029 | 0.01 |
| 3DMRE — full brain | ||||
| realG* [Pa] | 1814 ± 155 | 1737 ± 211 | 1574 ± 145 | < 0.01 |
| imagG* [Pa] | 588 ± 94 | 525 ± 143 | 423 ± 92 | < 0.01 |
| |G*| [Pa] | 1970 ± 176 | 1876 ± 255 | 1682 ± 170 | < 0.01 |
| φ | 0.26 ± 0.04 | 0.22 ± 0.07 | 0.17 ± 0.07 | 0.01 |
| 3DMRE — lentiform nucleus | ||||
| realG* [Pa] | 1942 ± 182 | 1804 ± 180 + | 1745 ± 213 + | 0.05 |
| imagG* [Pa] | 620 ± 129 | 530 ± 158 | 437 ± 128 + | < 0.01 |
| |G*| [Pa] | 2101 ± 199 | 1955 ± 213 + | 1850 ± 233 + | 0.01 |
| φ | 0.29 ± 0.08 | 0.23 ± 0.11 | 0.16 ± 0.11 + | < 0.01 |
Values are means ± SD; +1-way ANOVA (age as covariate); post hoc between-group analysis (unpaired t-test).
P < 0.05 vs. controls.
P < 0.05 vs. PD.
Correlation of MRE parameters and clinical severity (PD: UPDRS motor part during ON; PSP: PSP staging system according to Golbe scale (Golbe and Ohman-Strickland, 2007)).
| PD | PD | PSP | PSP | |
|---|---|---|---|---|
| MMRE — full brain | ||||
| μ | 0.030 | 0.907 | − 0.285 | 0.285 |
| α | − 0.376 | 0.124 | − 0.431 | 0.095 |
| MMRE — lentiform nucleus | ||||
| μ | 0.487 | 0.041 | − 0.259 | 0.334 |
| α | − 0.068 | 0.790 | − 0.153 | 0.570 |
| 3DMRE — full brain | ||||
| realG* | − 0.592 | 0.010 | − 0.536 | 0.032 |
| imagG* | − 0.582 | 0.011 | − 0.503 | 0.047 |
| |G*| | − 0.589 | 0.010 | − 0.540 | 0.031 |
| φ | − 0.533 | 0.023 | − 0.500 | 0.048 |
| 3DMRE — lentiform nucleus | ||||
| realG* | − 0.593 | 0.012 | − 0.511 | 0.043 |
| imagG* | − 0.486 | 0.048 | − 0.420 | 0.105 |
| |G*| | − 0.607 | 0.010 | − 0.506 | 0.046 |
| φ | − 0.478 | 0.053 | − 0.548 | 0.028 |
Fig. 4Correlation of 3DMRE (|G*|) and severity of clinical symptoms (UPDRSIII-ON) in PD patients.